ATE357230T1 - Neue prodrugs für antimicrobielle amidine - Google Patents

Neue prodrugs für antimicrobielle amidine

Info

Publication number
ATE357230T1
ATE357230T1 AT00950293T AT00950293T ATE357230T1 AT E357230 T1 ATE357230 T1 AT E357230T1 AT 00950293 T AT00950293 T AT 00950293T AT 00950293 T AT00950293 T AT 00950293T AT E357230 T1 ATE357230 T1 AT E357230T1
Authority
AT
Austria
Prior art keywords
amidine
antimicrobial
new prodrugs
prodrugs
new
Prior art date
Application number
AT00950293T
Other languages
English (en)
Inventor
David W Boykin
M Syed Rahmathullah
Richard R Tidwell
James E Hall
Original Assignee
Univ North Carolina
Univ Georgia State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Univ Georgia State Res Found filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE357230T1 publication Critical patent/ATE357230T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00950293T 1999-07-08 2000-07-06 Neue prodrugs für antimicrobielle amidine ATE357230T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14282699P 1999-07-08 1999-07-08

Publications (1)

Publication Number Publication Date
ATE357230T1 true ATE357230T1 (de) 2007-04-15

Family

ID=22501448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00950293T ATE357230T1 (de) 1999-07-08 2000-07-06 Neue prodrugs für antimicrobielle amidine

Country Status (9)

Country Link
US (3) US6486200B1 (de)
EP (1) EP1242059B1 (de)
JP (1) JP2003504329A (de)
AT (1) ATE357230T1 (de)
AU (1) AU779923B2 (de)
CA (1) CA2377902A1 (de)
DE (1) DE60034063T2 (de)
ES (1) ES2282127T3 (de)
WO (1) WO2001003685A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4368582B2 (ja) * 2001-01-13 2009-11-18 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 牛ウイルス性下痢ウイルス(bvdv)感染およびc型肝炎ウイルス(hcv)感染を処置するのに有用な化合物、方法、および組成物
EP1837024A3 (de) * 2001-01-13 2007-11-14 University Of North Carolina At Chapel Hill Verbindungen, Verfahren und Zusammensetzung zur Behandlung von Boviner Virusdiarrhoe-Virus (BVDV)-Infektion und Hepatitis-C-Virus (HCV)-Infektion
US7163955B2 (en) 2001-01-13 2007-01-16 The University Of North Carolina At Chapel Hill Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6951880B2 (en) 2002-05-16 2005-10-04 Genelabs Technologies, Inc. Aryl and heteroaryl compounds as antibacterial and antifungal agents
AU2003295923B2 (en) * 2002-11-27 2007-10-25 Georgia State University Research Foundation, Inc. Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents
WO2005009377A2 (en) * 2003-07-23 2005-02-03 University Of Kentucky Research Foundation Novel oral bioavailable prodrugs
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US7382516B2 (en) * 2004-06-18 2008-06-03 Angstrom, Inc. Discretely controlled micromirror with multi-level positions
JP2008500965A (ja) * 2004-03-17 2008-01-17 エムペックス・ファーマシューティカルズ・インコーポレーテッド 細菌の排出ポンプ阻害剤の使用および投与
US7994225B2 (en) * 2004-03-17 2011-08-09 Rempex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections
US7160946B2 (en) * 2004-04-01 2007-01-09 National Starch And Chemical Investment Holding Corporation Method to improve high temperature cohesive strength with adhesive having multi-phase system
CN101351204B (zh) * 2005-12-29 2011-01-12 富山化学工业株式会社 芳脒衍生物及其盐、以及含有它们的抗真菌药
GB0619325D0 (en) * 2006-09-30 2006-11-08 Univ Strathclyde New compounds
DE102007013855A1 (de) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
WO2009043902A1 (en) * 2007-10-05 2009-04-09 Universite De Mons Hainaut Bisbenzimidazoles as antimalarial agents
WO2009151627A2 (en) * 2008-06-12 2009-12-17 The Charles Stark Draper Laboratory, Inc. Endosome-disrupting compostions and conjugates
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
EP2690832B1 (de) * 2011-03-25 2019-11-13 Nec Corporation Kommunikationsvorrichtung, kommunikationssystem und kommunikationsverfahren
CN111646971B (zh) * 2020-07-22 2022-05-31 河南省三生药业有限公司 一种合成4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR76941B (de) * 1980-11-07 1984-09-04 Sumitomo Chemical Co
YU45662B (sh) * 1983-09-20 1992-07-20 Berol Nobel (Suisse) S.A. Postupak za dobijanje fenmedifama ili dezmedifama
US4595683A (en) * 1984-04-27 1986-06-17 William H. Rorer, Inc. 3- and 5-[bicyclic ether or bicyclic alkylene thioether]alkylene amino thiatriazines, and their pharmaceutical uses
GB8714873D0 (en) * 1987-06-25 1987-07-29 Bp Chemicals Additives Additives
US5260473A (en) * 1991-04-29 1993-11-09 Monsanto Company Preparation of urethane and carbonate products
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
US5521189A (en) 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5668166A (en) * 1995-06-07 1997-09-16 Georgia State University Research Foundation, Inc. Methods of inhibiting pneumocystis carinii pneumonia and compounds useful therefor
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors

Also Published As

Publication number Publication date
US6486200B1 (en) 2002-11-26
CA2377902A1 (en) 2001-01-18
JP2003504329A (ja) 2003-02-04
AU6341600A (en) 2001-01-30
US20020019437A1 (en) 2002-02-14
ES2282127T3 (es) 2007-10-16
DE60034063T2 (de) 2007-07-26
AU779923B2 (en) 2005-02-17
EP1242059A2 (de) 2002-09-25
EP1242059B1 (de) 2007-03-21
DE60034063D1 (de) 2007-05-03
WO2001003685A3 (en) 2002-07-11
WO2001003685A2 (en) 2001-01-18
US20030092755A1 (en) 2003-05-15
US6503940B2 (en) 2003-01-07
US6649652B2 (en) 2003-11-18

Similar Documents

Publication Publication Date Title
DE60034063D1 (de) Neue prodrugs für antimicrobielle amidine
ATE204875T1 (de) Fungizide tetrahydrofurane
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
CY1107634T1 (el) Φαρμακευτικη συνθεση
ATE297203T1 (de) Antithrombotische mitteln
ATE306261T1 (de) Antithrombosemittel
NO20014925L (no) Farmasöytiske forbindelser
DE60132011D1 (de) Nitroderivate als arzneimittel für auf entzündungen beruhende erkrankungen
ATE235462T1 (de) Metalloproteinase-inhibitoren
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
ATE296827T1 (de) Heteropolycyclische inhibitoren
SE0101082D0 (sv) Novel use
NO982873L (no) 1-metylkarbapenemderivater
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
NO970340D0 (no) Organiske forbindelser
SE0004101D0 (sv) New use
EA200100140A1 (ru) Терапевтическая композиция на основе флавоноидов для применения в лечении опухолей цитотоксическими агентами
ATE247108T1 (de) Antifungale tetrahydrofurane
TW200600084A (en) Anti-coronavirus compounds
SE0004827D0 (sv) Therapeutic compounds
DE50104100D1 (de) Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c
BR0015156A (pt) Pró-drogas de higromicina a
TR199902820T2 (xx) Multisiklik eritromisin t�revleri.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties